Form 8K ImmuCell Corporation For: 9 July
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
ImmuCell Corporation (ICCC)
ImmuCell Corporation stock price live, this page displays NASDAQ ICCC stock exchange data. View the ICCC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the ImmuCell Corporation real time stock price chart below.
What Is the ImmuCell Corporation Stock Price Today?
The ImmuCell Corporation stock price today is 6.180.
What Is the Stock Symbol for ImmuCell Corporation?
The stock symbol for ImmuCell Corporation is ""ICCC.""
What Stock Exchange Does ImmuCell Corporation Trade On?
ImmuCell Corporation is listed and trades on the NASDAQ stock exchange.
Is ImmuCell Corporation a Good Stock to Buy?
Determining whether ImmuCell Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ICCC quote. (ISIN: US4525253062)
What Is the ImmuCell Corporation Stock Price Today?
The ImmuCell Corporation stock price today is 6.180.
What Is the Stock Symbol for ImmuCell Corporation?
The stock symbol for ImmuCell Corporation is ""ICCC.""
What Stock Exchange Does ImmuCell Corporation Trade On?
ImmuCell Corporation is listed and trades on the NASDAQ stock exchange.
Is ImmuCell Corporation a Good Stock to Buy?
Determining whether ImmuCell Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ICCC quote. (ISIN: US4525253062)
NASDAQ
Currency in USD
6.180
0.000(0.00%)
Real-time Data·
Fair Value
An estimate of a ImmuCell's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.180
6.210
52 wk Range
3.340
7.600
ICCC Scorecard
Full Analysis
High return over the last year
Earnings results expected in 7 days
1/2
Fair Value
An estimate of a ImmuCell's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.1806.210
52 wk Range
3.3407.600
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ICCC Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a ImmuCell's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Liquid assets exceed short term obligations
- ImmuCell reports 18% sales growth in Q2 2025
- Investing.com
- Form 8K ImmuCell Corporation For: 17 June
- Investing.com
- Form 8K ImmuCell Corporation For: 9 July
- Investing.com
- ImmuCell reports 18% sales growth in Q2 2025
- Investing.com
- Form 8K ImmuCell Corporation For: 25 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
ImmuCell Corporation Company Profile
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
ImmuCell Corporation Earnings Call Summary for Q1/2025
- ImmuCell's Q1 2025 revenue hit $8.1M, up 11% YoY; EPS at $0.16; stock surged 9.78% to $4.91 post-earnings
- Gross margin improved to 42% from 37% in previous quarter; adjusted EBITDA reached $2.3M, up from $705,000 in Q1 2024
- New bulk powder format introduced for First Defense product; company targets $40M annual production capacity
- CEO Michael Brigham: 'Business becoming larger, more diverse and complex'; CFO Tim Fiori emphasized gross margin importance
- Company cautious on revenue projections; optimistic about Repayne product's investigational use and potential market feedback
Last Updated: 15/05/2025, 14:58
Read Full TranscriptCompare ICCC to Peers and Sector
Metrics to compare | ICCC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipICCCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −205.5x | −3.4x | −0.5x | |
PEG Ratio | −2.19 | −0.19 | 0.00 | |
Price/Book | 1.9x | 2.0x | 2.6x | |
Price / LTM Sales | 2.0x | 10.0x | 3.3x | |
Upside (Analyst Target) | - | 130.2% | 43.5% | |
Fair Value Upside | Unlock | 11.2% | 6.9% | Unlock |
Earnings
Latest Release
May 14, 2025
EPS / Forecast
0.16 / --
Revenue / Forecast
8.07M / --
People Also Watch
FAQ
What Stock Exchange Does ImmuCell Trade On?
ImmuCell is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for ImmuCell?
The stock symbol for ImmuCell is "ICCC."
What Is the ImmuCell Market Cap?
As of today, ImmuCell market cap is 55.85M.
What Is ImmuCell's Earnings Per Share (TTM)?
The ImmuCell EPS (TTM) is -0.03.
When Is the Next ImmuCell Earnings Date?
ImmuCell will release its next earnings report on 13 Aug 2025.
From a Technical Analysis Perspective, Is ICCC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has ImmuCell Stock Split?
ImmuCell has split 1 times.
How Many Employees Does ImmuCell Have?
ImmuCell has 71 employees.
What is the current trading status of ImmuCell (ICCC)?
As of 07 Aug 2025, ImmuCell (ICCC) is trading at a price of 6.18, with a previous close of 6.18. The stock has fluctuated within a day range of 6.18 to 6.21, while its 52-week range spans from 3.34 to 7.60.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.